Mark McClung was appointed to Chief Operating Officer, overseeing Sangamo’s core functions, including European business operations, corporate and business development, product strategy and planning, alliance management, patient advocacy, government relations, investor relations, corporate communications, facilities and information technology. Sangamo’s teams in France and the UK will report to Mark. In this newly expanded role, Mr. McClung draws on more than a decade of experience in management and executive positions at leading pharmaceutical companies.

“I am excited to take on a larger leadership role at Sangamo as we continue to pioneer genomic medicine. I look forward to building the capabilities that will bring new therapies and hope to patients who need both,” McClung shared.

Mr. McClung assumes the role of Chief Operating Officer after serving as Sangamo’s Chief Business Officer, a position he started in May 2020. In that role, he oversaw commercial planning strategies, corporate and business development, and alliance management. He will continue to function as Sangamo’s chief business officer as part of his new accountabilities.

Before joining Sangamo, he held the title of Vice President and General Manager of Global Oncology Commercial at Amgen and Chief Commercial Officer at Onyx Pharmaceuticals. He launched his career in the pharmaceutical industry with GlaxoSmithKline. Mr. McClung has a B.A. in Human Kinetics and Biomedical Sciences from the University of Guelph in Ontario, Canada, and completed graduate coursework at York University in Toronto and Wharton Business School at the University of Pennsylvania.